Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCSW) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for HeartSciences (HSCSW) over the last 5 years, with Q4 2025 value amounting to -$334208.0.

  • HeartSciences' Change in Accured Expenses fell 5503.74% to -$334208.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $109573.0, marking a year-over-year increase of 13902.3%. This contributed to the annual value of $16791.0 for FY2025, which is 12860.96% up from last year.
  • As of Q4 2025, HeartSciences' Change in Accured Expenses stood at -$334208.0, which was down 5503.74% from $166718.0 recorded in Q3 2025.
  • HeartSciences' Change in Accured Expenses' 5-year high stood at $371484.0 during Q2 2022, with a 5-year trough of -$477475.0 in Q3 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $21737.0 (2023), whereas its average is $19211.6.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 99702.04% in 2022, then skyrocketed by 47292.09% in 2025.
  • HeartSciences' Change in Accured Expenses (Quarter) stood at $144380.0 in 2021, then soared by 71.17% to $247141.0 in 2022, then tumbled by 126.67% to -$65901.0 in 2023, then tumbled by 227.11% to -$215566.0 in 2024, then plummeted by 55.04% to -$334208.0 in 2025.
  • Its Change in Accured Expenses was -$334208.0 in Q4 2025, compared to $166718.0 in Q3 2025 and $261319.0 in Q2 2025.